Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease

​ObjectiveCompared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is a...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open diabetes research & care 2020-01, Vol.8 (1), p.e000991
Main Authors: Mayeda, Laura, Katz, Ronit, Ahmad, Iram, Bansal, Nisha, Batacchi, Zona, Hirsch, Irl B, Robinson, Nicole, Trence, Dace L, Zelnick, Leila, de Boer, Ian H
Format: Article
Language:English
Subjects:
Age
Aged
Amputation
Biomarkers - analysis
Blood Glucose - analysis
Blood Glucose Self-Monitoring
Case-Control Studies
Diabetes
Diabetes Mellitus, Type 2 - complications
Diabetic retinopathy
Epidemiology
Family medical history
Female
Follow-Up Studies
Foot diseases
Glomerular Filtration Rate
Glucose monitoring
Glycated Hemoglobin A - analysis
Hemoglobin
Humans
Hyperglycemia
Kidney diseases
Male
Middle Aged
Pathophysiology/Complications
Peripheral Nervous System Diseases - diagnosis
Peripheral Nervous System Diseases - etiology
Peripheral Nervous System Diseases - metabolism
Peripheral neuropathy
Prognosis
Prospective Studies
Questionnaires
Renal Insufficiency, Chronic - complications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:​ObjectiveCompared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is associated with DPN symptoms among participants with type 2 diabetes mellitus (type 2 DM) and moderate-to-severe CKD.​Research design and methodsWe enrolled 105 people with type 2 DM treated with insulin or sulfonylurea, 81 participants with CKD (estimated glomerular filtration rate (eGFR)
ISSN:2052-4897
2052-4897
DOI:10.1136/bmjdrc-2019-000991